90 results about "Retinitis" patented technology

The invention provides a method of optical imaging comprising providing a sample to be imaged, measuring and correcting aberrations associated with the sample using adaptive optics, and imaging the sample by optical coherence tomography. The method can be used to image the fundus of a human eye to provide diagnostic information about retinal pathologies such as macular degeneration, retinitis pigmentosa, glaucoma, or diabetic retinopathy. The invention further provides an apparatus comprising an adaptive optics subsystem and a two-dimensional optical coherence tomography subsystem.

Normal tissue complications limit curative broadbeam radiotherapy to tumors including lung cancer. Radiation retinitis causing blindness limits quality of life and long term survival for patients with ocular melanoma. This invention pertains to alternative, normal tissue sparing 100 to 1,000 Gy microbeam radiations with least normal tissue complications and concomitant radio-immunotherapy by innate immune response of epidermis and dermis to low dose radiation with 50 kV X-rays. Total body skin radiation with former airport passenger screening machines with 50 kV X-ray is disclosed. Microbeams are generated without contaminating scatter and neutron radiations from collinear gamma ray and electron beam produced by inverse Compton interaction with high energy laser and electron beam and from proton and carbon ion beams in tissue equivalent cylindrical collimators. Extracorporeal immunotherapy and chemotherapy and apheresis of mutated subcellular particles released into circulation in response to cancer-therapies are by clinical continuous flow ultracentrifugation combined chromatography.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

Disclosed are ribozymes, as well as compositions, vectors, virus particles, host cells, and therapeutic kits comprising them useful in the treatment of diseases of the eye, including retinopathy and macular degeneration, and the amelioration of symptoms of such diseases including loss of vision, retinitis, and blindness.

The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for intravitreal delivery of therapeutic gene constructs to retinal neuron cells, and specifically to ON bipolar cells, of the mammalian eye, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of retinitis pigmentosa, melanoma-associated retinopathy, and congenital stationary night blindness.

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

Described herein are methods and compositions for genomic editing. Clustered regularly interspaced short palindromic (CRISPR) allows for highly selective targeting and alteration of genetic loci. Here, the Inventors demonstrate CRISPR as capable of being used in living animals to prophylactically prevent a genetic disease from manifesting. Targeting and disruption of mutated rhodopsin gene prevents progression of retinitis pigmentosa in the retinal cells of a transgenic rat model. Such techniques allow for treatment methods in subjects with dominant genetic mutations, often associated with lack of a gene product, or a toxic gene product. The described technology effectively abrogates deleterious effects due to the presence of a mutated gene copy allowing the normal function of the wild-type protein to prevent cell and vision loss. The efficacy of these in vivo mechanisms are widely extensible to similar dominant negative gene mutations causing disease, or other types of genetic disease.

The invention discloses a Chinese herba preparation for treating eye inflammation and a preparation method of the traditional Chinese preparation. The Chinese herba preparation is prepared by cassia occidentalis, concha haliotidis, bat dung, centipeda minima, emilia sonchifolia, pipewort, feather cockscomb seeds, wild chrysanthemum flower, rehmannia glutinosa, Chinese yam, pulp of dogwood fruit, rhizoma alismatis, tuckahoe, cortex moutan radicis, wolfberry, cape jasmine, mother of pearl, scouring rush, bamboo shavings, caltrop and roots of hairy asiabell. The Chinese herba preparation is a Chinese medicinal herb preparation, and has a good treatment effect for acute or chronic conjunctivitis, central retinitis and optic neuritis, and after the Chinese herba preparation is clinically used for treating more than totally 100 cases of eye diseases of more than 600 patients for more than ten years, effective rate can be higher than 90%. In addition, according to clinical verifications, the Chinese herba preparation does not cause drug resistance and does not have toxic and side effects.

The troxerutin powder for injection includes troxerutin 2-100 wt% and excipient 0-98 wt%, and the excipient is one of mannitol, lactose, glycine, sorbic alcohol, low molecular weight dextran, glucose, cane sugar and hydrolysate gel. It is bacteria-free powder or bacteria-free freeze dried produce. The present invention is used in treating ischemic cerebral vascular diseases, central retinitis, arteriosclerosis, thrombotic phlebitis, varicosity, etc. and has the advantages of stability, fast dissolution in water and high safety.

Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Closbidium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, acute pancreatitis, psoriasis, infertility and allergic disorders such as rhinitis, conjunctivitis, and urticaria.

A system and methods for compensating for retinitis pigmentosa for a user include using a head-mounted and user-controllable device that can minify the image to more closely match the user's reduced field of view. The user may adjust the amount of minification and may also adjust the magnification of the image.

The invention discloses a traditional Chinese medicine composition for treating central retinitis. The traditional Chinese medicine composition is prepared from the following crude drugs in parts by weight: 10-20 parts of barbary wolfberry fruits, 10-20 parts of chrysanthemum, 5-10 parts of loofah sponge, 0 part of glossy privet fruits, 5-10 parts of suberect spatholobus stems, 8-12 parts of semen cassiae, 8-15 parts of cicada slough, 10-20 parts of angelica sinensis, 8-12 parts of angelica sylvestris, 10-20 parts of fructus forsythiae, 8-12 parts of safflowers and 5-10 parts of eclipta alba. The selected crude drugs simultaneously take the effects of dispelling the wind and clearing away heat, promoting blood circulation to remove blood stasis, soothing the liver and dredging collaterals, nourishing yin and dispelling wind, clearing liver and improving vision and the like. Through clinical application, the traditional Chinese medicine composition is found to be rapid in taking effects, high in curative ratio, low in cost, safe and reliable.

The invention discloses an eye ointment for treating eye diseases. The eye ointment is prepared from the following raw materials in parts by weight: chrysanthemum, pen grass, fragrant solomonseal rhizome, mint, divaricate saposhnikovia root, mulberry leaf, amur corktree bark, tabasheer, notopterygium root, goat gall, borneol, coptis root, wild celery, snake gall, dahurian angelica root, heather honey, calculus bovis, fineleaf schizonepeta herb, common anemarrhena, subopposite milkwort herb, wild ginger, Chinese angelica, tea leaf and sesame oil. The entire formula has the effects of clearing away heat and toxic materials, promoting blood circulation to dispel blood stasis, resisting bacteria, reducing inflammation, clearing liver and improving vision, can be used for treating various eye diseases such as puffy eyes, lachrymation, eye dryness and itching, bursting pain, eye white congestion, conjunctivitis, viral conjunctivitis, retinitis, blurred vision and the like, has a simple preparation process, and is fully absorbed by patients.

The invention discloses a new liver and kidney nourishing decoction preparation (a novel medicament delivery system) for treating hepatitis and a preparation method thereof, which belong to the field of biomedicine. The new preparation comprises six medicinal materials, namely coastal glehnia root, dwarf lilyturf tuber, Chinese angelica, rehmannia root, barbary wolfberry fruit and szechwan Chinaberry fruit, and a proper amount of extract of a coptis component serving as main raw materials, and is prepared by the following steps of: extracting and separating; properly adding medicinal auxiliary materials; and finally preparing by the conventional process of formulations such as sprays, ointments (or syrups), pills, aerosols, dispersible tablets, orally disintegrating tablets, targeting preparations, controlled release preparations and the like. Through improved technology, the curative effect of the conventional compound prescription is further improved, so the technical requirement of controllable quality of the modern Chinese traditional medicine is met, the side effect is also reduced, and the compliance of a clinical medicament is improved. The new preparation has the unique effects of treating difficult and complicated diseases such as the hepatitis, hepatocirrhosis, liver cancer, gastritis, pregnancy-induced hypertension syndrome, tubal ligation syndrome, herpes zoster, central retinitis, recurrent aphtha, other gynecological diseases and the like, so that the new preparation has unique clinical application value.

The invention discloses a traditional Chinese medicine composition for treating central retinitis, which is prepared from the following raw materials in parts by weight: 10-40 parts of phaseolus calcaratus, 1-16 parts of rhizoma alismatis, 5-25 parts of poria, 1-16 parts of radix stephaniae tetrandrae, 2-22 parts of radix astragali, 5-25 parts of radix salviae miltiorrhizae, 1-20 parts of Chinese angelica, 1-20 parts of rhizoma atractylodis macrocephalae, 5-25 parts of earthworm, 1-20 parts of herba epimedii, 1-20 parts of cassia twig, 8-28 parts of caulis spatholobi and 1-13 parts of liquorice root. The traditional Chinese medicine composition disclosed by the invention has moderate property and good curative effect, and is used for treating central retinitis without laser photocoagulation.

The invention discloses a drug combination for treating centrality serous chorioretinitis, composed of angelica, root of rehmannia, white paeony root, chrysanthemum, the rhizome of chuanxiong, savia miltiorrhiza, tuckahoe, rhizoma polygonati, white caltrop, semen cassiae and pearls. The drug combination has the efficacies of replenishing qi and nourishing blood, clearing heat and cooling blood, promoting blood circulation and removing blood stasis as well as removing nebula and improving eyesight, formula is scientific and curative effect is definite.

Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).

The invention discloses a preparation method of inosine and a composition injection thereof. The injection is composed of raw materials of inosine and sodium chloride, and accessories of glycine and water for injection. 100ml of the composition contains 0.6 wt% of inosine, 0.9 wt% of sodium chloride and 0.15-0.25wt% of glycine. The injection is a large volume injection prepared from inosine and pharmaceutically acceptable accessories and has stable quality; and the injection is used for auxiliary treatment of leukopenia, thrombocytopenia, heart failure, angina pectoris and hepatitis caused by various reasons, and can also be used for auxiliary treatment of optic atrophy and central retinitis. The invention also involves preparation of a composition injection containing polygeline and inosine; the composition injection is a large volume injection prepared from polygeline, inosine and pharmaceutically acceptable excipients and has stable quality; and the composition injection is used for acute normovolemic hemodilution, improves microcirculation and prevents the occurrence of ischemic and hypoxic injury of tissues.

The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt or inclusion compound. The present invention provides fumagillol derivatives having the following characteristics: increased inhibiting effect on angiogenesis, low toxicity, excellent solubility and chemical stability as compared to conventional angiogenesis inhibitors. The compounds of the present invention can be used as an anti-cancer medicine, inhibitor of cancer metastasis, or the therapeutic agent for treating rheumatic arthritis, psoriasis, diabetic retinitis or obesity.

The invention discloses a near-infrared fundus therapeutic instrument, and relates to the technical field of medical instruments for eye diseases. The near-infrared fundus therapeutic instrument comprises a head-mounted main body and a controller, wherein the head-mounted main body is provided with a near-infrared light source electrically connected with the controller, the near-infrared light source is used for irradiating the fundus of a tested user, the near-infrared light source has a plurality of preset light emitting powers, and the controller is used for controlling the near-infrared light source to select the corresponding preset light emitting power so as to adapt to the fundus disease condition of the tested user. The near-infrared fundus therapeutic instrument can conveniently and effectively assist in treating fundus diseases such as central serous retinitis, senile macular degeneration, and the like.

The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.

An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.